Impact of Visual Field Restriction on Visual Exploration (NCT04360291) | Clinical Trial Compass
UnknownNot Applicable
Impact of Visual Field Restriction on Visual Exploration
France45 participantsStarted 2019-11-04
Plain-language summary
To communicate with the observer and guide his gaze on the canvas, painters have developed different stylistic processes that artists, in the manner of scientists, have acquired on the functioning of human visual perception. This direct communication between the artist and the observer is strongly impacted for people with visual impairments.
In order to improve the accessibility and autonomy of visually impaired people in museums and to allow each observer to feel the visual and emotional experience closest to the original work of the artist, it is essential to identify the modifications. perceptive generated by the constriction of vision
Who can participate
Age range
18 Years – 65 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Groupe 1
Inclusion Criteria:
* no visual pathology
* Age ≥ 18 and \<65 years
* Binocular visual acuity ≥8 / 10th or ≤ +0.10 logMAR
* Comprehension of the written and spoken French language
* Signed consent to participate in the study
* Health insurance affiliation
* Visit to an ophthalmologist less than a year old
Exclusion Criteria:
* Pregnant or lactating woman
* Ocular pathology that may interfere with planned assessments
* Treatment that may interfere with planned assessments
* Participation in another study that may interfere with this study.
* Severe pathology unbalanced or interfering with planned assessments.
* Neurological deficit including history of epileptic pathology, photosensitive epilepsy, sensory-motor coordination disorders, vestibular or cerebellar pathology
* Inability to give consent personally.
* Adults protected by law.
Groupe 2
Inclusion Criteria:
* Retinopathy pigmentary dystrophy rods-cones.
* Binocular visual acuity ≥4 / 10 (≤0.4 logMAR).
* Horizontal diameter of the residual Goldmann field of view ≤ 25 ° of binocular diameter at III4.
* Comprehension of the French language, written or oral.
* Signed consent
* Visual assessment less than 6 months old
Exclusion Criteria:
* Pregnant or nursing woman.
* Ocular pathology that may interfere with planned assessments.
* Treatment that may interfere with planned assessments.
* Severe pathology unbalanced or interfering with planned assessments.
* Participation in another study that may interfere wi…
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Eye movements
Timeframe: through study completion,, an average of 1 year
2
Fixation strategy
Timeframe: through study completion,, an average of 1 year
3
Target location accuracy
Timeframe: through study completion,, an average of 1 year
Trial details
NCT IDNCT04360291
SponsorCentre Hospitalier National d'Ophtalmologie des Quinze-Vingts